|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lobbezoo DJ, van Kampen RJ, Voogd AC,
Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ,
Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic
breast cancer subtypes: The hormone receptor/HER2-positive subtype
is associated with the most favorable outcome. Breast Cancer Res
Treat. 141:507–514. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
den Brok WD, Speers CH, Gondara L, Baxter
E, Tyldesley SK and Lohrisch CA: Survival with metastatic breast
cancer based on initial presentation, de novo versus relapsed.
Breast Cancer Res Treat. 161:549–556. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhou W, Yue Y, Xiong J, Li W and Zeng X:
The role of locoregional surgery in de novo stage IV breast cancer:
A meta-analysis of randomized controlled trials. Cancer Treat Rev.
129(102784)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Giaquinto AN, Sung H, Newman LA, Freedman
RA, Smith RA, Star J, Jemal A and Siegel RL: Breast cancer
statistics 2024. CA Cancer J Clin. 74:477–495. 2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lu YS, Im SA, Colleoni M, Franke F, Bardia
A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, et al: Updated
overall survival of ribociclib plus endocrine therapy versus
endocrine therapy alone in pre- and perimenopausal patients with
HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III
Randomized clinical trial. Clin Cancer Res. 28:851–859.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
The effect of abemaciclib plus fulvestrant on overall survival in
hormone receptor-positive, ERBB2-Negative breast cancer that
progressed on endocrine therapy-MONARCH 2: A Randomized clinical
trial. JAMA Oncol. 6:116–124. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cristofanilli M, Rugo HS, Im SA, Slamon
DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi
S, et al: Overall survival with palbociclib and fulvestrant in
women with HR+/HER2- ABC: Updated exploratory analyses of PALOMA-3,
a double-blind, phase III Randomized study. Clin Cancer Res.
28:3433–3442. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang Z, Zhou X, Tong Y, Zhu L, Zhao R and
Huang X: Surgery for primary tumor benefits survival for breast
cancer patients with bone metastases: A large cohort retrospective
study. BMC Cancer. 21(222)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Soran A, Dogan L, Isik A, Ozbas S,
Trabulus DC, Demirci U, Karanlik H, Soyder A, Dag A, Bilici A, et
al: The effect of primary surgery in patients with de novo stage IV
breast cancer with bone metastasis only (Protocol BOMET MF 14-01):
A multi-center, prospective registry study. Ann Surg Oncol.
28:5048–5057. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tinterri C, Sagona A, Barbieri E, Di Maria
Grimaldi S, Jacobs F, Zambelli A, Trimboli RM, Bernardi D, Vinci V
and Gentile D: Loco-regional treatment of the primary tumor in de
novo metastatic breast cancer patients undergoing front-line
chemotherapy. Cancers (Basel). 14(6237)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zardavas D, Irrthum A, Swanton C and
Piccart M: Clinical management of breast cancer heterogeneity. Nat
Rev Clin Oncol. 12:381–394. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vitale I, Shema E, Loi S and Galluzzi L:
Intratumoral heterogeneity in cancer progression and response to
immunotherapy. Nat Med. 27:212–224. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gu TQ, Xiao YL and Shao ZM: Intratumor
heterogeneity in breast cancer: Tracing its origins and translating
findings into clinical practice. Precision Medicine and
Engineering. 1(100006)2024.
|
|
15
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bartlett JMS, Bilous M, Ellis IO,
Fitzgibbons P, et al: Human epidermal growth factor receptor 2
testing in breast cancer: American society of clinical
oncology/college of American pathologists clinical practice
guideline focused update. J Clin Oncol. 36:2105–2122.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wolff AC, Somerfield MR, Dowsett M,
Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA and
Allison KH: Human epidermal growth factor receptor 2 testing in
breast cancer: ASCO-College of American pathologists guideline
update. J Clin Oncol. 41:3867–3872. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Modi S, Jacot W, Yamashita T, Sohn J,
Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al:
Trastuzumab deruxtecan in previously treated HER2-Low advanced
breast cancer. N Engl J Med. 387:9–20. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bardia A, Hu X, Dent R, Yonemori K,
Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura
C, et al: Trastuzumab deruxtecan after endocrine therapy in
metastatic breast cancer. N Engl J Med. 391:2110–2122.
2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lu S, Wu J, Fang Y, Wang W, Zong Y, Chen
X, Huang O, He JR, Chen W, Li Y, et al: The impact of surgical
excision of the primary tumor in stage IV breast cancer on
survival: a meta-analysis. Oncotarget. 9:11816–11823.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Badwe R, Hawaldar R, Nair N, Kaushik R,
Parmar V, Siddique S, Budrukkar A, Mittra I and Gupta S:
Locoregional treatment versus no treatment of the primary tumour in
metastatic breast cancer: An open-label randomised controlled
trial. Lancet Oncol. 16:1380–1288. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khan SA, Zhao F, Goldstein LJ, Cella D,
Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, et al:
Early local therapy for the primary site in de novo stage IV breast
cancer: Results of a Randomized clinical trial (EA2108). J Clin
Oncol. 40:978–987. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fitzal F, Bjelic-Radisic V, Knauer M,
Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P,
Soelkner L, et al: Impact of breast surgery in primary metastasized
breast cancer: outcomes of the prospective Randomized phase III
ABCSG-28 POSYTIVE trial. Ann Surg. 269:1163–1169. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Visvader JE: Cells of origin in cancer.
Nature. 469:314–322. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Holdaway IM and Bowditch JV: Variation in
receptor status between primary and metastatic breast cancer.
Cancer. 52:479–485. 1983.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ramón Y, Cajal S, Sesé M, Capdevila C,
Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, Hernández-Losa J and
Castellví J: Clinical implications of intratumor heterogeneity:
Challenges and opportunities. J Mol Med (Berl). 98:161–177.
2020.PubMed/NCBI View Article : Google Scholar
|
